跳至主要内容

Medicilon’s Lead Optimization in Drug Discovery

 Medicilon’s medicinal chemistry involves the application of a number of specialized disciplinary approaches all focused on the ultimate goal of drug discovery.  Drug target identification and validation, rational (target-based) drug design, structural biology, computational-based drug design, methods development (chemical, biochemical and computational), and “Hit-to-lead” development are all aspects of medicinal chemistry.  The techniques and approaches of chemical biology, synthetic organic chemistry, combinatorial (bio)chemistry, mechanistic enzymology, computational chemistry, chemical genomics and high-throughput screening are all used and applied by medicinal chemists towards drug discovery.

 

Lead Optimization

Medicilon has completed dozens of drug research projects for clients and successfully identified several drug candidates for clinical trials. Our team provides the following services:more details

Target Assessment – Drug Targets
HITs Identification
Lead Optimization
Clinical Candidate Nomination
Computer Aided Drug Design
SAR Study

Lead optimization strategy

From early phase chemistry, through in vitro toxicity screening and metabolism profiling, to establishing in vivo bioavailability; we put facilities and expertise, state-of-the-art equipment and high quality accommodations at your disposal. No “standard” strategy exists that is suitable for the lead optimization of developmental drugs. Therefore,our first focus in assisting you with lead optimization is not to screen a high number of compounds with as many screening studies as possible,but to start designing your most efficient and effective drug screening strategy that addresses major aspects of ADMET.

Lead Optimization

Lead optimization is an operationally diverse stage of the drug discovery process in which the chemical structures of compounds or biologics are modified to improve target specificity and selectivity, plus pharmacodynamic, pharmacokinetic and toxicological properties to produce a preclinical drug candidate. This process requires detailed characterization of lead compound series and lead biologics, including data related to toxicity, efficacy, stability and bioavailability.

Lead optimization (LO) is one of the most expensive and time-consuming stages of the drug development process.  Multiple factors make it more challenging given the need to improve the probability of technical success:

• The number of LO programs running simultaneously
• The number of molecules within each of those programs
• The need for integrated safety and efficacy endpoints
• The need for reproducible, decision-driving data

When you partner with Medicilon, you will work collaboratively with a dedicated team of experts assigned specifically to your project—sharing information,identifying and interpreting findings and providing you with the critical information you need to move forward with a successful candidate while prioritizing your lead optimization pipeline. This strong and productive relationship will continue until our team enables you to achieve your goal: the selection of a successful candidate for further development.

Contact us

Email : marketing@medicilon.com
Tel : +86 021 58591500

Tips : Above is part of Lead Optimization Services and Lead Optimization in Drug Discovery. You can also CONTACT US with any question or enquiry you may have. We will be happy to discuss your needs in detail and design an appropriate plan of action.

评论

此博客中的热门博文

Medicilon and Binhui Biopharmaceutical Have Reached a Strategic Collaboration to Jointly Draw a New Blueprint for the Development of New Biological Drugs

  On March 18, Medicilon and Binhui Biopharmaceutical (Binui Bio) announced a strategic collaboration.  The two parties will work together to jointly explore the possibilities in cutting-edge fields such as oncolytic viruses, nucleic acid drugs and protein drugs. Gather and Work Together to Create Advantages      Facilitate the Research and Development of Oncolytic Viruses, Nucleic Acids, Proteins and Other Drugs As a one-stop biopharmaceutical comprehensive preclinical R&D service CRO, Medicilon has been developing and accumulating for 20 years, always adhering to the spirit of innovation, and has successfully constructed bi/multi-specific antibodies,  ADCs ,  mRNA vaccines ,  small nucleic acid drugs ,  PROTAC , and  CGT technical service platform  that have helped 421 INDs obtain clinical approval.  It is this outstanding achievement that has earned Medicilon wide recognition in the industry and laid a solid foundation f...

The Launch Meeting was Held by Medicilon and DAC Biotech of the Contract Research on ADC Preclinical Study

  Chuansha, Shanghai, Nov. 8th, 2019 — Medicilon held the launch meeting with Hangzhou DAC Biotech Co., Ltd to initiate the   preclinical study   of the antibody-drug-conjugate (ADC)  DXC005, including the   pharmacology study ,   DMPK study   and the   safety evaluation . Medicilon has previously completed integrated  preclinical research  on ADC drugs cooperating with DAC Biotech and other companies. Two of them has been approved by NMPA and entered Phase I clinical trials. About Hangzhou DAC Biotech Co., Ltd Hangzhou DAC Biotech, Co., Ltd was officially registered in HEDA Area, Hangzhou City, Zhejiang Province, China around the end of Year 2012, and is located nearby the bank of beautiful Qiantang River. The company focuses on developing conjugate of monoclonal antibody and small molecular cytotoxic drug, both of which are banded together with smart linkers. About Antibody-Drug-Conjugate (ADC) ADCs ...

A Nickel-Catalyzed Reductive Alkylation of Aryl Bromides and Chlorides for Sp3-Sp2 Bond Formation

  In 2012, a nickel-catalyzed reductive alkylation method of aryl bromides and chlorides was reported. Under the optimized conditions, a variety of aryl and vinyl bromides as well as active aryl chloride can be reductively coupled with alkyl bromides in high yields. The protocols were highly functional-group tolerant and the reactions were not air or moisture sensitive. The reaction showed different chemoselectivity than conventional cross-coupling reactions. Substrates bearing both anelectrophilic and nucleophilic carbon resulted in selective coupling at the electrophilic carbon (R-X) and no reaction occurred at the nucleophilic carbon (R-[M]). The 2010 Nobel Prize in Chemistry was awarded for the Pd-catalyzed cross-coupling, and in the past decade the progress in cross-coupling has not only had a significant impact on academic research but has also influenced the industrial synthetic application. The transition-metal-catalyzed union of nucleophilic organo-boronic acids with elect...